From our partner, KPGM: The rules of engagement in the global pharmaceutical industry are changing rapidly with disruption in this industry already well underway. Two seismic shifts are starting to take effect. First, a re-balancing of power across the healthcare value chain is forcing a downward...

If you are working in the pharma, medtech or biotechnology industry in the areas of development, compliance, regulatory, It security or risk management, then this webinar is exactly for you. Rising to the data challenge: Genomics can bring significant benefits to healthcare systems, by accelerating clinical...

Hyperion Hotel Basel | 22-23 May 2019 Progressing translation of protein degradation probes into safe, effective therapeutics. The European Protein Degradation Congress will create an open forum for 200+ industry players to share data alongside hearing the latest understanding of the ubiquitin pathway from expert academics. Expect to meet...

To develop a scientific discovery into a life-changing drug or technology, it takes experts from various fields. We have collaborated with Labiotech.eu to paint a picture of all the players in Basel’s Biotech and Pharma ecosystem. [caption id="attachment_335694" align="alignnone" width="706"] Be part of the ecosystem and...

Lonza, a pharmaceutical company from Basel, has published pleasing half-year results, with positive momentum driven by its new Consumer Health division. Lonza has reported 8.2 per cent organic sales growth to 3.079 billion Swiss francs – a figure that includes Capsugel’s results from the first six months...

 The physician and pharmacologist Nicole Onetto is a member of the Board of Directors at the Basilea Pharmaceutica AG. In the Interview that was featured in Basilea’s annual report she talks about current challenges in oncology. Great strides are being made in the long-term treatment of...

Basel is among the European biotech hubs with the most exciting companies as named by labiotech.eu. The industry platform highlighted businesses including Actelion, CRISPR Therapeutics and Polyphor. The industry platform labiotech.eu has named the European biotech hubs with the “most exciting biotech companies” based on feedback...

Xconomy National — Arch Venture Partners co-founder and managing director Bob Nelsen is widely regarded as one of the most astute and successful life science investors and company builders in the game. The list of his portfolio company wins (if you think of raising money, going public,...

The Swiss biotech industry continued to grow in 2017. Reaching record figures in sales and capital investments in companies, according to a new report. New biotech facilities are expected to further increase export volumes. The 297 companies in the Swiss biotech industry increased their sales by...